SOUTH EASTON, Mass., Oct. 8 — Pressure BioSciences, Inc. (Nasdaq: PBIO) (“PBI”) today provided an update on various corporate activities, including the presentation of favorable data generated by scientists at Amgen, Inc. on the Company’s pressure cycling technology (“PCT”), the scheduled presentation by Dr. Paul Pevsner of the NYU School of Medicine on the use of PCT in identifying potential protein biomarkers in colon cancer samples, and guidance relative to forecasted Q32008 and FY2008 sales of the Company’s Barocycler instruments.

1) Amgen Presentation: data were presented by scientists from Amgen at the 35th meeting of the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS) comparing PCT to their standard overnight procedure and the popular CEM, Inc. microwave-assisted technique for the digestion of a therapeutic monoclonal antibody. Amgen scientists reported that, “Pressure cycling was shown to be most effective at achieving complete digestion in a short time, without unintended perturbation of the molecule. Microwave digestion did not achieve complete digestion and induced oxidation of methionine residues.” The authors concluded that, “PCT represents an increase in throughput and efficiency of at least 20-fold over the current conditions … pressure cycling provided the most effective method for digesting monoclonal antibodies.”

2) Dr. Paul Pevsner Presentation: Dr. Pevsner, Associate Professor of Pharmacology at the NYU School of Medicine, is scheduled to speak at the “Discovery2Diagnostics” Conference (San Diego, CA) on Monday, October 20th. Dr. Pevsner’s talk, entitled “MALDI Imaging and Mass Spectrometry Identification of Colorectal Cancer Biomarkers”, will include a discussion on the advantages of PCT versus other sample preparation methods available today. Dr. Pevsner is also expected to present data on the discovery of several proteins that he and his colleagues have found in colon cancer samples using PCT that have not been previously found in similar samples using other sample preparation techniques.

3) Guidance on Barocycler Sales: on August 14th, the Company announced that it expected to install at least fourteen (14) PCT Sample Preparation Systems during Q32008. The Company is pleased to announce that it has installed 17 PCT Systems, as compared to 7 in the second quarter of 2008. Furthermore, the Company expects to meet or exceed its previously announced full year guidance of 40 installations.

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “The continued publications and presentations from early adopters of PCT is helping us tremendously in our commercialization efforts. We attribute a significant portion of our recent commercial success to testimonials like the ones highlighted above, that herald the merits of pressure cycling technology in various applications of life sciences, as well as the advantages of PCT over other sample preparation methods available today. We would like to congratulate our customers and collaborators for their important research studies and for their continued support of PCT.”